Rivastigmine Tartrate Capsule
NDC Package 71209-014-03

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Rivastigmine Tartrate capsules is rivastigmine is used to treat confusion (dementia) related to Alzheimer's disease and to Parkinson's disease. This formulation utilizes a capsule delivery system. Marketed by Cadila Pharmaceuticals Limited, this product is identified by NDC 71209-014 and is authorized under FDA application ANDA203844.

Identification & Billing

NDC Package Code
71209-014-03
Package Description
60 CAPSULE in 1 BOTTLE
Product Code
71209-014
11-Digit Billing Format
71209001403
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Rivastigmine Tartrate
Non-Proprietary Name
Rivastigmine Tartrate
Substance Name
Rivastigmine Tartrate
Dosage Form
Capsule - A solid oral dosage form consisting of a shell and a filling. The shell is composed of a single sealed enclosure, or two halves that fit together and which are sometimes sealed with a band. Capsule shells may be made from gelatin, starch, or cellulose, or other suitable materials, may be soft or hard, and are filled with solid or liquid ingredients that can be poured or squeezed.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
RIVASTIGMINE TARTRATE 4.5 mg/1
Pharmacologic Class
Usage Information
Rivastigmine is used to treat confusion (dementia) related to Alzheimer's disease and to Parkinson's disease. Rivastigmine does not cure either of these diseases, but it may improve memory, awareness, and the ability to perform daily functions. This medication works by restoring the balance of natural substances (neurotransmitters) in the brain.

Regulatory & Marketing

Labeler Name
Cadila Pharmaceuticals Limited
Product Type
Human Prescription Drug
FDA Application #
ANDA203844
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
02-11-2014
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (71209-014). Click a package code to view its specific billing and regulatory data.

71209-014-10
500 CAPSULE in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 71209-014-03 identifies a specific commercial package of 60 capsule in 1 bottle of Rivastigmine Tartrate, a human prescription drug labeled by Cadila Pharmaceuticals Limited. This capsule is formulated for oral use and contains rivastigmine tartrate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Cadila Pharmaceuticals Limited on February 11, 2014. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Rivastigmine is used to treat confusion (dementia) related to Alzheimer's disease and to Parkinson's disease. Rivastigmine does not cure either of these diseases, but it may improve memory, awareness, and the ability to perform daily functions. This medication works by restoring the balance of natural substances (neurotransmitters) in the brain.

How is this Cadila Pharmaceuticals Limited product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 71209001403. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
71209-014-03
11-Digit CMS (5-4-2)
71209-0014-03

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.